Distinct allelic expression patterns of imprinted IGF2 in adenocarcinoma and squamous cell carcinoma of the lung

Ferguson-Smith AC: Genetic imprinting: silencing elements have their say. Curr Biol. 10:R872–R875. 2000.

Ohlsson R, Nystrom A, Pfeifer-Ohlsson S, et al: IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. Nat Genet. 4:94–97. 1993.

Rainier S, Johnson LA, Dobry CJ, et al: Relaxation of imprinted genes in human cancer. Nature. 22:747–749. 1993.

Cui H, Horon IL, Ohlsson R, Hamilton SR and Feinberg AP: Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med. 4:1276–1280. 1998.

Nakagawa H, Chadwick RB, Peltomaki P, et al: Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci USA. 98:591–596. 2001.

Takano Y, Shiota G and Kawasaki H: Analysis of genomic imprinting of insulin-like growth factor 2 in colorectal cancer. Oncology. 59:210–216. 2000.

Kohda M, Hoshiya H, Katoh M, et al: Frequent loss of imprinting of IGF2 and MEST in lung adenocarcinoma. Mol Carcinog. 31:184–191. 2001.

Xu W, Fan H, He X, Zhang J and Xie W: LOI of IGF2 is associated with esophageal cancer and linked to methylation status of IGF2 DMR. J Exp Clin Cancer Res. 25:543–547. 2006.

Byun HM, Wong HL, Birnstein EA, et al: Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res. 67:10753–10758. 2007.

Zuo QS, Yan R, Feng DX, et al: Loss of imprinting and abnormal expression of the insulin-like growth factor 2 gene in gastric cancer. Mol Carcinog. 50:390–396. 2011.

Cheng L, Alexander RE, Maclennan GT, et al: Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol. 25:347–369. 2012.

Trajkovic-Arsic M, Kalideris E and Siveke JT: The role of insulin and IGF system in pancreatic cancer. J Mol Endocrinol. 50:R67–R74. 2013.

Vincent EE, Elder DJ, Curwen J, et al: Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor. PLoS One. 8:e669632013.

Nie ZL, Pan YQ, He BS, et al: Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system. Mol Cancer. 11:862012.

Uejima H, Lee MP, Cui H and Feinberg AP: Hot-stop PCR: a simple and general assay for linear quantitation of allele ratios. Nat Genet. 25:375–376. 2000.

Maenaka S, Hikichi T, Imai MA, Minamoto T and Kawahara E: Loss of imprinting in IGF2 in colorectal carcinoma assessed by microdissection. Oncol Rep. 15:791–795. 2006.

Kaneda A, Wang CJ, Cheong R, et al: Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci USA. 104:20926–20931. 2007.

Liu P, Morrison C, Wang L, et al: Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis. 33:1270–1276. 2012.

Suzuki A, Mimaki S, Yamane Y, et al: Identification and characterization of cancer mutations in Japanese lung adenocarcinoma without sequencing of normal tissue counterparts. PLoS One. 8:e734842013.

Douillard JY, Shepherd FA, Hirsh V, et al: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 28:744–752. 2010.